Newsroom
Category
May 27, 2016
The agency has already awarded more than half of its $3 billion funding allotment. Read the full story at San Antonio Business Journal
May 26, 2016
A novel antiangiogenic gene therapy, added to another antiangiogenic agent, Avastin (bevacizumab), led to significantly better overall survival (OS) in recurrent glioblastoma multiforme (GBM) compared with historical patients treated with Avastin alone, a small phase 2 trial showed. Read the full story at Cure Today
May 25, 2016
The Cancer Prevention & Research Institute of Texas has awarded nearly $11 million to the University of Texas Health Science Center at San Antonio in its latest funding round. That award includes $5 million to help establish the Texas Pediatric Patient-Derived Xenograft Facility. Read the full story at San Antonio Business Journal
May 21, 2016
The Greehey Children’s Cancer Research Institute at the UT Health Science Center at San Antonio received $10.9 million from the Cancer Prevention & Research Institute of Texas (CPRIT)?a larger amount than any other academic institution in the state. Read the full story at North San Antonio Chamber
May 20, 2016
The Cancer Therapy & Research Center of the Health Science Center garnered $10.9 million from the Cancer Prevention & Research Institute of Texas (CPRIT)―a larger amount than any other academic institution in the state.
May 20, 2016
The Cancer Therapy & Research Center of the UT Health Science Center San Antonio garnered $10.9 million from the Cancer Prevention & Research Institute of Texas (CPRIT) ― a larger amount than any other academic institution in the state.
